Announced Tue, 14 Jul · 12:26 IST

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-14.4%1-day move
₹19.50
prior close
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-14.4-14.4-16.3-12.8-16.1-15.1
Up moveDown movePending
AI summary

Venmax Drugs & Pharmaceuticals has submitted a routine quarterly compliance certificate to BSE as required under SEBI's Depositories Regulations. The certificate, issued by the company's Registrar and Share Transfer Agent (CIL Securities Limited), confirms that shares sent for dematerialisation by depository participants during the quarter ended June 30, 2026 were properly verified, accepted, and recorded in the company's Register of Members. It also confirms that these securities remain listed on the stock exchange. The filing was signed by Priyanka Agarwal, Company Secretary, on July 14, 2026.

Likely market impact

This is a standard regulatory housekeeping filing with no material impact on the business, financials, or shareholders. Investors should view it as routine compliance and not a trigger for any trading action.